Claims for Patent: 5,610,054

Summary for Patent: 5,610,054

Title:	Enzymatic RNA molecule targeted against Hepatitis C virus
Abstract:	An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis C virus.
Inventor(s):	Draper; Kenneth G. (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/182,968
Patent Claims:	1. An enzymatic RNA molecule which is active to specifically cleave RNA of hepatitis C virus (HCV). 2. The enzymatic RNA molecule of claim 1 which specifically cleaves RNA of HCV in the 5'non-translated region. 3. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is in a hammerhead motif. 4. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is in a hairpin, hepatitis Delta virus, group I intron, or RNaseP RNA motif. 5. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule specifically cleaves the RNA sequence comprising any of SEQ. ID. NOS. 1-8, and wherein said enzymatic RNA molecule is in a hepatitis Delta virus configuration. 6. The enzymatic RNA molecule of claim 1 which specifically cleaves RNA of HCV in the RNA encoding the core (c) region. 7. The enzymatic RNA molecule of claim 1 which specifically cleaves RNA of HCV in the RNA encoding the proteases NS3 or NS2NS3. 8. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule specifically cleaves the RNA sequence comprising any of SEQ. ID. NOS. 001-506, and wherein said enzymatic RNA molecule is in a hepatitis Delta virus configuration. 9. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule specifically cleaves the RNA sequence comprising any of SEQ. ID. NOS. 001-506, and wherein said enzymatic RNA molecule is in a hammerhead configuration. 10. The enzymatic RNA molecule of any of claims 1-5 and 6-9, wherein said enzymatic RNA molecule comprises at least one sugar modification. 11. The enzymatic RNA molecule of any of claims 1-5 and 6-9, wherein said enzymatic RNA molecule comprises at least one phosphate backbone modification. 12. The enzymatic RNA molecule of claim 10, wherein said sugar modification is a 2'-O-methyl group. 13. The enzymatic RNA molecule of claim 11, wherein said phosphate modification is a phosphorothioate group. 14. An expression vector including a nucleic acid encoding the enzymatic RNA molecule of may of claims 1-5, and 6-9, in a manner which allows expression of said enzymatic RNA molecule within a mammalian cell in vitro. 15. A mammalian cell including the enzymatic RNA molecule of any of claims 1-5, and 6-9, in vitro. 16. The cell of claim 15, wherein said cell is a human cell.

Details for Patent 5,610,054

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2014-03-11
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2014-03-11
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2014-03-11